Lyell Immunopharma Stock Forecast, Price & News

Lyell Immunopharma (NASDAQ:LYEL) Frequently Asked Questions

Is Lyell Immunopharma a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lyell Immunopharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Lyell Immunopharma stock.
View analyst ratings for Lyell Immunopharma or view top-rated stocks.

What stocks does MarketBeat like better than Lyell Immunopharma?

Wall Street analysts have given Lyell Immunopharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Lyell Immunopharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Lyell Immunopharma's next earnings date?

Lyell Immunopharma is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Lyell Immunopharma.

How were Lyell Immunopharma's earnings last quarter?

Lyell Immunopharma, Inc. (NASDAQ:LYEL) announced its quarterly earnings data on Thursday, August, 12th. The company reported ($1.25) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.54) by $0.29. The company earned $2.63 million during the quarter, compared to analyst estimates of $2.42 million.
View Lyell Immunopharma's earnings history.

What price target have analysts set for LYEL?

4 equities research analysts have issued twelve-month target prices for Lyell Immunopharma's shares. Their forecasts range from $22.00 to $30.00. On average, they anticipate Lyell Immunopharma's share price to reach $25.50 in the next twelve months. This suggests a possible upside of 83.2% from the stock's current price.
View analysts' price targets for Lyell Immunopharma or view top-rated stocks among Wall Street analysts.

Who are Lyell Immunopharma's key executives?

Lyell Immunopharma's management team includes the following people:

• Dr. Richard D. Klausner, Exec. Chairman (Age 69, Pay $1.43M)
• Ms. Elizabeth Homans, CEO & Director (Age 55, Pay $1.14M)
• Ms. Heather D. Turner, Chief Gen. Counsel & Sec. (Age 48, Pay $917.08k)
• Mr. Stephen J. Hill, Chief Technical Operations Officer (Age 50, Pay $722.58k)
• Mr. Charles W. Newton, Chief Financial Officer (Age 50)
• Nellie Dillery, Director of Accounting
• Mr. Richard Goold Ph.D., Chief Information Officer (Age 61)
• Ms. Lisa Ryan, Chief People Officer (Age 54)
• Dr. Nicholas Restifo M.D., Exec. VP of Research (Age 60)
• Ms. Elaine Cheung, Sr. VP of Corp. Strategy & Bus. Devel.

Who are some of Lyell Immunopharma's key competitors?

Some companies that are related to Lyell Immunopharma include Ono Pharmaceutical (OPHLF), Teva Pharmaceutical Industries (TEVA), Dr. Reddy's Laboratories (RDY), Maravai LifeSciences (MRVI), Bausch Health Companies (BHC), Zai Lab (ZLAB), Grifols (GRFS), Mirati Therapeutics (MRTX), Jazz Pharmaceuticals (JAZZ), Ascendis Pharma A/S (ASND), Biohaven Pharmaceutical (BHVN), United Therapeutics (UTHR), Evotec (EVTCY), Legend Biotech (LEGN) and CureVac (CVAC).
View all of LYEL's competitors.

When did Lyell Immunopharma IPO?

(LYEL) raised $425 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 25,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO.

What is Lyell Immunopharma's stock symbol?

Lyell Immunopharma trades on the NASDAQ under the ticker symbol "LYEL."

When does Lyell Immunopharma's lock-up period expire?

Lyell Immunopharma's lock-up period expires on Tuesday, December 14th. Lyell Immunopharma had issued 25,000,000 shares in its public offering on June 17th. The total size of the offering was $425,000,000 based on an initial share price of $17.00. After the end of Lyell Immunopharma's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Who are Lyell Immunopharma's major shareholders?

Lyell Immunopharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (0.18%).

Which major investors are buying Lyell Immunopharma stock?

LYEL stock was acquired by a variety of institutional investors in the last quarter, including Baillie Gifford & Co..

How do I buy shares of Lyell Immunopharma?

Shares of LYEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lyell Immunopharma's stock price today?

One share of LYEL stock can currently be purchased for approximately $13.92.

How much money does Lyell Immunopharma make?

Lyell Immunopharma has a market capitalization of $3.33 billion.

How many employees does Lyell Immunopharma have?

Lyell Immunopharma employs 189 workers across the globe.

What is Lyell Immunopharma's official website?

The official website for Lyell Immunopharma is www.lyell.com.

How can I contact Lyell Immunopharma?

The company can be reached via phone at 650-695-0677.